OcuTerra Therapeutics, Inc is a Boston-based company that is dedicated to revolutionizing the treatment of ophthalmic diseases. With their innovative approach, they aim to address the significant unmet need for earlier and non-invasive treatment of diabetic retinopathy, a common eye condition. Their topical eye drop, OTT166, has the potential to transform the standard of care by inhibiting integrins central to diabetic retinal disease.
By creating a clear vision for the future of ophthalmic treatment, OcuTerra Therapeutics is at the forefront of scientific advancements in the field. Through their commitment to research and clinical trials, they are paving the way for improved patient outcomes and providing valuable solutions for both physicians and patients alike.
Generated from the website